ArticleWorld journal of microbiology & biotechnology2026
Pan-genome guided identification and functional characterisation of three putative bacteriocin variants from Brevibacillus laterosporus.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Brevibacillus laterosporus (B. laterosporus) is a significant probiotic bacterium known for producing multiple secondary metabolites with notable antibacterial activity. In this study, bioinformatic tools such as FastANI and Roary were employed to analyze genomic similarity and construct the B. laterosporus pan-genome. The software platforms antiSMASH and BAGEL4 were used to predict biosynthetic gene clusters (BGCs) and identify bacteriocins. Core candidate bacteriocins were subsequently subjected to heterologous expression in E. coli, followed by nickel column purification and concentration. Their antibacterial activity was systematically evaluated using agar diffusion assays, minimum inhibitory concentration (MIC) determinations, time-kill curves, scanning electron microscopy (SEM), and live/dead bacterial staining in Listeria monocytogenes (L. monocytogenes). Pan-genome analysis revealed an open genome for B. laterosporus, comprising 2,840 core genes. KEGG enrichment analyses indicated that these core genes were significantly associated with pathways responsible for the biosynthesis of antimicrobial compounds, including secondary metabolite, pan-quinone, and terpenoid quinone biosynthesis. AntiSMASH predicted 1,654 BGCs, predominantly non-ribosomal peptide synthase (NRPS), polyketide synthase (PKS), and heterocyclic amine-associated antimicrobial protein synthesis clusters. Moreover, BAGEL4 predicted three putative core candidate bacteriocin variants (BreL1, BreL2, and BreL3), all of which exhibited pronounced antibacterial activity against L. monocytogenes. Among these, BreL1 demonstrated the most robust activity, causing morphological changes consistent with membrane-associated damage. Collectively, this study elucidates the open pan-genome architecture and the metabolically rich secondary metabolome of B. laterosporus, identifies three putative bacteriocin variants with active antibacterial efficacy against L. monocytogenes, which provides a theoretical foundation for developing natural antimicrobial agents.
Indexed as
Identifiers
41999472What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.